LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LumiQuick Diagnostics Showcases Rapid Tests Across Multiple Clinical Applications

By LabMedica International staff writers
Posted on 18 Nov 2026

LumiQuick Diagnostics (Santa Clara, CA, USA) is showcasing its portfolio of rapid diagnostic tests and immunoassay solutions at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. Exhibiting in Hall 3, Stand D25-4, the company is highlighting its capabilities across infectious disease testing, drugs-of-abuse screening, cardiac and tumor markers, fertility testing, and consumer self-testing. With more than two decades of experience in in vitro diagnostics (IVD), LumiQuick provides diagnostic products and manufacturing services to healthcare providers, laboratories, and distributors worldwide.

Among the company's key offerings is its QuickProfile rapid-test portfolio, designed for point-of-care and laboratory applications. The infectious disease range includes assays for malaria, dengue, Zika, chikungunya, influenza A/B, H. pylori, adenovirus, rotavirus, HIV, and syphilis. The portfolio also encompasses tests for cardiac markers, tumor markers, fertility hormones, and vitamin D, supporting a broad range of clinical diagnostic applications.


Image: At Hall 3, Stand D25-4, LumiQuick Diagnostics is highlighting tests for infectious diseases, drugs of abuse, cardiac and tumor markers, fertility, and self-testing. (Photo courtesy of LumiQuick Diagnostics)
Image: At Hall 3, Stand D25-4, LumiQuick Diagnostics is highlighting tests for infectious diseases, drugs of abuse, cardiac and tumor markers, fertility, and self-testing. (Photo courtesy of LumiQuick Diagnostics)

LumiQuick also offers an extensive drugs-of-abuse (DOA) testing portfolio, including single-test strips, single-drug cards, multi-drug panels, and multi-panel cups. The QuickProfile DOA range covers substances such as methamphetamine, cocaine, opiates, THC, fentanyl, and synthetic cannabinoids. These products provide different testing formats for drug screening applications in healthcare and laboratory settings.

The company's broader portfolio includes the Aoxre OxisResearch range, which provides assays for measuring oxidative stress biomarkers, antioxidants, DNA damage, and related indicators. These products support research into oxidative, nitrosative, and inflammatory processes associated with various medical conditions. In addition to its diagnostic products, LumiQuick offers original equipment manufacturing (OEM) and original design manufacturing (ODM) services, supporting partners in developing and marketing diagnostic solutions under their own brands.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®

Latest Medica 2026 News

77 Elektronika Highlights Urinalysis Solutions for Diverse Laboratory Needs
18 Nov 2026  |   Medica 2026

Genrui Biotech Showcases Range of Clinical Diagnostic Instruments
18 Nov 2026  |   Medica 2026

BPM Presents Urine-Based Kidney Disease Risk Test at MEDICA 2026
18 Nov 2026  |   Medica 2026